Axa
MRTX

Axa’s Mirati Therapeutics, Inc. Common Stock MRTX Stock Holding History

Axa’s Portfolio MRTX Stock Details MRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-28,824
Closed -$2.01M – 1235
2022
Q3 		$2.01M Buy
28,824
+135
+0.5% +$9.99K 0.01% 757
2022
Q2 		$1.93M Sell
28,689
-551
-2% -$35K 0.01% 782
2022
Q1 		$2.4M Sell
29,240
-1
-0% -$102 0.01% 798
2021
Q4 		$4.29M Buy
29,241
+347
+1% +$53.9K 0.01% 699
2021
Q3 		$5.11M Buy
28,894
+1,073
+4% +$173K 0.01% 675
2021
Q2 		$4.49M Sell
27,821
-2,110
-7% -$339K 0.01% 736
2021
Q1 		$5.13M Sell
29,931
-3,752
-11% -$743K 0.02% 703
2020
Q4 		$7.4M Buy
33,683
+1,182
+4% +$256K 0.02% 597
2020
Q3 		$5.4M Sell
32,501
-302
-0.9% -$41.3K 0.02% 600
2020
Q2 		$3.75M Buy
32,803
+5,571
+20% +$540K 0.01% 697
2020
Q1 		$2.09M Sell
27,232
-1,819
-6% -$163K 0.01% 724
2019
Q4 		$3.74M Buy
29,051
+724
+3% +$69.8K 0.02% 690
2019
Q3 		$2.21M Sell
28,327
-43
-0.2% -$4.04K 0.01% 847
2019
Q2 		$2.92M Buy
+28,370
New +$2.21M 0.01% 788

Other funds holding MRTX

ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
AH
Aviva Holdings New Providence, Bahamas $20.5M AUM 117.01% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return

Axa's MRTX Position: Q4 2022 in Review

Axa sold out of Mirati Therapeutics, Inc. Common Stock (MRTX) in Q4 2022, closing a stake of 28,824 shares — an estimated $2.01M sold.

Axa first reported a position in MRTX in Q2 2019 and held it in 14 quarters. The position peaked at $7.4M in Q4 2020. 233 funds tracked by Wall St. Rank hold MRTX as of Q4 2022.

  • Axa reported no remaining Mirati Therapeutics, Inc. Common Stock position as of Q4 2022 after selling out during the quarter.
  • Axa sold 28,824 Mirati Therapeutics, Inc. Common Stock shares in Q4 2022, an estimated $2.01M.
  • Axa first reported a position in Mirati Therapeutics, Inc. Common Stock in Q2 2019 and held it in 14 quarters.
  • Axa's Mirati Therapeutics, Inc. Common Stock position peaked at $7.4M in Q4 2020.
  • 233 funds tracked by Wall St. Rank held Mirati Therapeutics, Inc. Common Stock as of Q4 2022.

Based on Axa's 13F filing for Q4 2022, filed 14 Feb 2023.